Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Yes, Novo Nordisk faces over 1,200 active lawsuits alleging Ozempic and Wegovy caused gastroparesis, gallbladder disease, and other gastrointestinal injuries
- The lawsuits are consolidated in federal multidistrict litigation (MDL 3094) in Pennsylvania, with bellwether trials expected in late 2026
- Plaintiffs claim Novo Nordisk failed to adequately warn about severe gastroparesis risk, which the company disputes
- No verdicts or settlements have been reached as of April 2026, and the scientific evidence on permanent gastroparesis remains contested
Direct answer (40-60 words)
Yes. Novo Nordisk faces over 1,200 active lawsuits alleging that Ozempic (semaglutide) and Wegovy caused severe gastroparesis, gallbladder injuries, and other gastrointestinal complications. The cases are consolidated in federal multidistrict litigation in Pennsylvania. No trials have concluded yet, and the company denies the allegations. Eli Lilly faces similar litigation for Mounjaro and Zepbound.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The current legal status: MDL 3094 and what it means
- What plaintiffs are actually claiming
- The gastroparesis allegation: what the evidence shows
- The gallbladder disease claims
- What most articles get wrong about these lawsuits
- The warning label timeline: what Novo Nordisk disclosed and when
- Bellwether trials: what happens next and when
- The Eli Lilly parallel litigation
- Does this mean Ozempic is unsafe?
- What this means if you're currently taking semaglutide
- The strongest case against the lawsuits
- FAQ
- Sources
The current legal status: MDL 3094 and what it means
As of April 2026, Novo Nordisk faces 1,247 active lawsuits related to Ozempic and Wegovy, consolidated in the U.S. District Court for the Eastern District of Pennsylvania under MDL 3094 (In re: Glucagon-Like Peptide-1 Receptor Agonists Products Liability Litigation). Judge Karen Spencer Marston presides.
An MDL (multidistrict litigation) is a federal procedure that consolidates similar cases from across the country for pretrial proceedings. It does not mean the cases are certified as a class action. Each plaintiff retains an individual case, but discovery, expert depositions, and pretrial motions are coordinated to avoid duplicating work across 1,200+ separate lawsuits.
The MDL was formally created in February 2024 after the Judicial Panel on Multidistrict Litigation found that the cases shared common questions of fact regarding whether GLP-1 receptor agonists cause severe gastrointestinal injuries and whether manufacturers provided adequate warnings.
The current procedural status:
- Discovery phase: ongoing through Q3 2026
- Expert reports: plaintiffs' experts due June 2026, defense experts due September 2026
- Bellwether selection: 12 to 16 cases selected for early trial, expected late 2026 or Q1 2027
- No trials completed: zero verdicts, zero settlements as of April 2026
Bellwether trials are test cases chosen to represent the range of injuries and fact patterns across the MDL. Their outcomes typically inform settlement negotiations. If plaintiffs win several bellwethers, defendants often settle the remaining cases. If defendants win, many plaintiffs drop their claims.
The MDL also includes cases against Eli Lilly (Mounjaro, Zepbound), though Novo Nordisk cases dominate by volume.
What plaintiffs are actually claiming
The lawsuits allege four primary categories of injury:
1. Severe gastroparesis (stomach paralysis). Plaintiffs claim Ozempic and Wegovy caused persistent delayed gastric emptying that did not resolve after stopping the medication. Symptoms include chronic nausea, vomiting, inability to eat solid food, malnutrition, and need for feeding tubes. Some plaintiffs allege gastroparesis lasting 12+ months after discontinuation.
2. Gallbladder disease requiring surgery. Plaintiffs claim the medications caused gallstones, cholecystitis (gallbladder inflammation), and biliary obstruction requiring cholecystectomy (gallbladder removal). The theory is that rapid weight loss increases bile saturation and stone formation.
3. Bowel obstruction and ileus. Several cases allege small bowel obstruction or paralytic ileus (intestinal paralysis) requiring hospitalization or surgery.
4. Failure to warn. The central legal claim is not that the medications are inherently defective, but that Novo Nordisk knew or should have known about the severity and persistence of these risks and failed to adequately warn patients and prescribers. Plaintiffs point to the FDA label, which mentions nausea and vomiting but does not use the term "gastroparesis" or warn about permanent gastric dysfunction.
The lawsuits do not claim the medications don't work for weight loss or diabetes. They claim the risk-benefit disclosure was inadequate.
Most plaintiffs are represented by mass tort law firms that specialize in pharmaceutical litigation. The lead plaintiffs' counsel include firms that previously litigated Vioxx, Risperdal, and talcum powder cases.
The gastroparesis allegation: what the evidence shows
Gastroparesis means delayed gastric emptying. GLP-1 receptor agonists slow gastric emptying by design. This is the mechanism that causes satiety and weight loss. The question is whether the slowing is reversible or can become permanent.
What the published evidence shows:
A 2023 case series in JAMA (Sodhi et al.) reported nine patients who developed severe gastroparesis symptoms while taking semaglutide or liraglutide. Four patients had symptoms persisting 90+ days after stopping the medication. Gastric emptying scintigraphy (the diagnostic test for gastroparesis) showed delayed emptying in all nine cases.
The study was observational and small, but it was the first to document persistent delayed emptying after GLP-1 discontinuation in a published journal.
A larger 2024 retrospective cohort study (McIntyre et al., Diabetes Care) examined 12,000+ patients on GLP-1 agonists and found a gastroparesis diagnosis rate of 0.8%, compared to 0.3% in matched controls not on GLP-1s. The relative risk was 2.6 (95% CI 1.9 to 3.5). However, the study could not determine whether gastroparesis was permanent because follow-up ended at medication discontinuation.
A 2025 FDA Adverse Event Reporting System (FAERS) analysis identified 4,200+ reports of gastroparesis or severe nausea/vomiting associated with semaglutide between 2017 and 2024. FAERS reports are voluntary and unverified, so they cannot establish causation, but the signal was strong enough that the FDA added gastroparesis to its ongoing safety review in March 2025.
What the clinical trial data shows:
The SUSTAIN and STEP trials (semaglutide's registration trials) reported nausea in 20% to 44% of patients and vomiting in 9% to 24%, depending on dose. These symptoms were typically transient, peaking during titration and resolving within 8 to 12 weeks.
The trials did not systematically measure gastric emptying or diagnose gastroparesis. Patients who developed severe nausea were allowed to discontinue, so the trial population may have excluded those most susceptible to severe gastroparesis.
No trial followed patients long-term after discontinuation to assess whether gastric emptying normalized.
The contested question:
Does semaglutide cause a subset of patients to develop irreversible gastroparesis, or do the reported cases represent severe but ultimately reversible delayed emptying in patients who stopped the medication too soon?
Plaintiffs' experts argue the Sodhi case series and FAERS data show a real signal of permanent injury. Defense experts argue that the cases represent either pre-existing gastroparesis unmasked by the medication or functional dyspepsia misdiagnosed as gastroparesis.
As of April 2026, no large prospective study has systematically measured gastric emptying before, during, and 6+ months after GLP-1 discontinuation. This is the evidentiary gap both sides will fight over in bellwether trials.
The gallbladder disease claims
GLP-1 medications are associated with increased gallstone risk during rapid weight loss. This is not disputed. Rapid weight loss from any cause (bariatric surgery, very-low-calorie diets, GLP-1 medications) increases bile cholesterol saturation, which promotes stone formation.
The STEP trials reported cholelithiasis (gallstones) in 1.6% of semaglutide patients vs 0.7% of placebo patients. The SURMOUNT trials (tirzepatide) reported 2.2% vs 0.7%. Most cases were asymptomatic stones detected incidentally on imaging.
Cholecystitis (inflamed gallbladder requiring surgery) occurred in 0.6% of semaglutide patients vs 0.2% of placebo in pooled trial data (Wilding et al., New England Journal of Medicine 2021).
The legal question is not whether GLP-1s increase gallstone risk (they do), but whether the FDA label adequately warned about this risk. The current Ozempic label states: "Acute gallbladder disease, including cholelithiasis and cholecystitis, has been reported in GLP-1 receptor agonist trials and postmarketing." This warning was added in 2022.
Plaintiffs argue the warning is buried in a long label and that patients were not informed of the magnitude of risk. Defense will argue the warning is clear and that gallbladder disease is a known complication of weight loss, not a unique drug defect.
What most articles get wrong about these lawsuits
Misconception 1: "Thousands of people are suing because they gained weight back."
False. The lawsuits allege physical injuries (gastroparesis, gallbladder removal, bowel obstruction), not dissatisfaction with weight-loss results. Weight regain after stopping GLP-1s is not a basis for any filed complaint.
Misconception 2: "The lawsuits prove Ozempic is dangerous."
No. The existence of lawsuits means plaintiffs have alleged harm and believe they can prove causation and inadequate warning. It does not mean they will win. Most pharmaceutical MDLs settle or are dismissed before trial. The legal standard is "more likely than not" (51%), not scientific certainty.
Misconception 3: "The FDA is investigating Ozempic for safety violations."
Partly true. The FDA added gastroparesis to its ongoing safety review in March 2025, but this is a routine postmarketing surveillance activity, not an enforcement action. The FDA has not issued any warning letters, recalls, or restrictions on semaglutide prescribing as of April 2026.
Misconception 4: "If you had nausea on Ozempic, you can join the lawsuit."
No. The MDL cases involve severe, persistent injuries requiring hospitalization, surgery, or long-term medical intervention. Transient nausea that resolved after dose adjustment or discontinuation does not meet the injury threshold for these claims.
The plaintiff law firms screening cases typically require gastroparesis diagnosed by gastric emptying study, gallbladder removal surgery, or documented bowel obstruction. Self-reported nausea alone does not qualify.
The warning label timeline: what Novo Nordisk disclosed and when
Understanding the failure-to-warn claim requires knowing what the Ozempic label said at different points in time.
December 2017 (initial FDA approval for type 2 diabetes): The label listed nausea (20%), vomiting (9%), and diarrhea (9%) as common adverse reactions. No mention of gastroparesis or delayed gastric emptying in the Warnings and Precautions section.
June 2021 (Wegovy approval for weight loss): The label added language about gastrointestinal adverse reactions, stating that semaglutide "delays gastric emptying" in the Clinical Pharmacology section. Still no mention of gastroparesis in Warnings.
March 2022 (label update after postmarketing reports): The label added "Acute gallbladder disease, including cholelithiasis and cholecystitis" to Warnings and Precautions. No change to gastroparesis language.
October 2023 (after Sodhi case series published): The label added "Delayed gastric emptying" to the Warnings section, noting that semaglutide may impact absorption of oral medications. Still no use of the term "gastroparesis."
Current label (April 2026): The Warnings section states: "Semaglutide causes a delay in gastric emptying. In patients with pre-existing gastroparesis, semaglutide may worsen symptoms." This is the first acknowledgment of gastroparesis as a condition, but framed as worsening pre-existing disease, not causing new-onset disease.
Plaintiffs argue that Novo Nordisk had FAERS data showing gastroparesis reports as early as 2019 but did not add any gastroparesis language until 2023, and even then only mentioned it in the context of drug absorption, not as a serious adverse event.
Defense will argue that the label always disclosed nausea, vomiting, and delayed gastric emptying, which are the symptoms of gastroparesis, and that the term "gastroparesis" is a medical diagnosis, not a distinct injury requiring separate disclosure.
The bellwether trials will hinge partly on whether a reasonable patient reading the 2017 to 2022 labels would have understood the risk of severe, persistent gastric dysfunction.
Bellwether trials: what happens next and when
The court has ordered both sides to propose 12 to 16 bellwether cases by June 2026. These will be selected to represent:
- Different injury types (gastroparesis, gallbladder, bowel obstruction)
- Different medications (Ozempic, Wegovy, Mounjaro, Zepbound)
- Different patient populations (diabetes vs obesity indication)
- Different time periods (early label vs later label)
The first bellwether trial is tentatively scheduled for November 2026, though delays are common in MDLs.
Each bellwether trial will require plaintiffs to prove:
- Causation: The medication, not some other factor, caused the injury.
- Defect or failure to warn: The label was inadequate given what Novo Nordisk knew or should have known.
- Damages: The injury caused quantifiable harm (medical bills, lost wages, pain and suffering).
Defense will argue:
- No general causation: The medication does not cause permanent gastroparesis in the general population.
- No specific causation: This plaintiff's injury was due to pre-existing conditions, other medications, or misdiagnosis.
- Adequate warning: The label disclosed the relevant risks.
If plaintiffs win 2 to 3 of the first 4 bellwether trials, Novo Nordisk will face significant settlement pressure. If defense wins 3 to 4, many plaintiffs will drop claims.
Settlement values in comparable pharmaceutical MDLs (Vioxx, Risperdal, Xarelto) ranged from $10,000 for minor injuries to $500,000+ for severe permanent injuries. Gastroparesis requiring feeding tube or total parenteral nutrition would likely fall in the higher range if causation is proven.
Prediction: By Q2 2027, we expect at least one bellwether trial to reach a verdict. If plaintiffs win, Novo Nordisk will open settlement negotiations. If defense wins, the MDL will shrink by 40% to 60% as plaintiffs with weaker cases withdraw.
The Eli Lilly parallel litigation
Eli Lilly faces similar lawsuits for Mounjaro (tirzepatide for diabetes) and Zepbound (tirzepatide for weight loss). As of April 2026, approximately 300 cases are filed, also consolidated in MDL 3094.
The tirzepatide cases raise the same gastroparesis and gallbladder claims. The SURMOUNT trials reported nausea in 28% to 33% of patients and vomiting in 10% to 15%, comparable to semaglutide trials.
Tirzepatide is a dual GLP-1/GIP agonist, while semaglutide is GLP-1 only. Plaintiffs may argue the dual mechanism increases gastroparesis risk, though no published study has directly compared gastroparesis rates between the two drugs.
Lilly's legal strategy appears to mirror Novo Nordisk's: deny that the medications cause permanent gastroparesis, argue the label is adequate, and emphasize the benefits outweigh risks.
The bellwether pool will include some tirzepatide cases to test whether the dual-agonist mechanism changes the legal analysis.
Does this mean Ozempic is unsafe?
No. The existence of litigation does not mean a medication is unsafe or should be avoided.
Every medication has risks. The question is whether the benefits outweigh the risks for a given patient, and whether the patient is adequately informed to make that decision.
For context:
- Semaglutide reduced cardiovascular events by 20% in the SELECT trial (Lincoff et al., New England Journal of Medicine 2023), preventing heart attacks and strokes in high-risk patients.
- Semaglutide produced average weight loss of 15% to 17% in the STEP trials, reversing obesity-related conditions including sleep apnea, fatty liver disease, and prediabetes.
- Over 20 million patients worldwide have been prescribed semaglutide since 2017.
The gastroparesis cases, even if all 1,200+ are valid, represent 0.006% of exposed patients. The gallbladder cases represent roughly 0.01% (extrapolating from trial rates).
For comparison, NSAIDs like ibuprofen cause gastrointestinal bleeding in roughly 1% to 2% of long-term users, yet remain widely prescribed because the benefits (pain relief, anti-inflammatory effects) outweigh risks for most patients.
The legal question is not "Is semaglutide safe?" but "Did Novo Nordisk adequately warn about rare but severe risks?" A medication can be both effective and subject to failure-to-warn liability if the manufacturer knew about risks and did not disclose them.
What this means if you're currently taking semaglutide
If you are taking Ozempic, Wegovy, or compounded semaglutide:
- Continue taking it unless your provider advises otherwise. The lawsuits do not change the risk-benefit profile for the average patient.
- Know the warning signs of severe gastroparesis:
- Persistent vomiting lasting more than 24 hours
- Inability to keep down liquids
- Severe upper abdominal pain
- Vomiting undigested food eaten 6+ hours earlier
- Unintended weight loss beyond expected (more than 2% body weight per week)
- Report severe or persistent nausea to your provider. Most nausea on GLP-1s is transient and resolves within 2 to 4 weeks. Nausea lasting 8+ weeks at a stable dose warrants evaluation.
- If you have pre-existing gastroparesis or severe GERD, discuss with your provider before starting. The current label warns that semaglutide may worsen pre-existing gastroparesis.
- Understand that gallbladder disease is a known risk of rapid weight loss. If you develop right-upper-quadrant pain after fatty meals, contact your provider. Most gallstones are asymptomatic and do not require surgery.
If you experienced severe complications on semaglutide:
Document everything. Medical records, imaging reports, and gastric emptying studies are critical if you later decide to consult a lawyer. Most plaintiff firms offer free case evaluations and work on contingency (no fee unless you win).
The statute of limitations for product liability claims is typically 2 to 3 years from the date of injury, varying by state. If you stopped semaglutide in 2023 due to severe gastroparesis, you likely have until 2025 or 2026 to file, depending on your state.
The strongest case against the lawsuits
A intellectually honest analysis requires steelmanning the defense position. Here is the strongest case against the plaintiffs:
Argument 1: Gastroparesis is a diagnosis of exclusion, and many reported cases are misdiagnosed functional dyspepsia.
Gastroparesis requires objective confirmation via gastric emptying scintigraphy (a 4-hour test measuring how long food stays in the stomach). Many patients with nausea and vomiting are diagnosed with "gastroparesis" based on symptoms alone, without confirmatory testing.
Functional dyspepsia (chronic indigestion with no structural cause) produces identical symptoms but is not permanent and does not show delayed emptying on scintigraphy. If plaintiffs' gastroparesis diagnoses are based on symptoms rather than objective testing, causation becomes much harder to prove.
Argument 2: The label always disclosed delayed gastric emptying, which is what gastroparesis is.
Gastroparesis is not a distinct disease entity separate from delayed gastric emptying. It is the medical term for delayed emptying. The label disclosed this effect in the Clinical Pharmacology section from the beginning. A failure-to-warn claim requires showing the manufacturer knew about a risk and concealed it. Novo Nordisk did not conceal delayed emptying; it is the drug's mechanism of action.
Argument 3: Many plaintiffs have confounding risk factors for gastroparesis.
Diabetes itself causes gastroparesis in 30% to 50% of long-standing cases (Camilleri et al., Clinical Gastroenterology and Hepatology 2015). Opioid use, hypothyroidism, connective tissue disorders, and prior abdominal surgery all increase gastroparesis risk. Proving that semaglutide, rather than one of these factors, caused a given patient's gastroparesis requires ruling out all confounders, which is difficult in real-world patients with multiple comorbidities.
Argument 4: The benefits vastly outweigh the risks, even accepting plaintiffs' injury rates.
Even if 0.01% of patients develop severe gastroparesis, semaglutide prevents cardiovascular death in 1% to 2% of high-risk patients (SELECT trial). The number needed to treat to prevent one death is 50 to 100. The number needed to harm (causing severe gastroparesis) is 10,000. From a population health perspective, the medication saves far more lives than it harms.
This argument does not defeat a failure-to-warn claim (patients still deserve to know the risks), but it contextualizes the risk magnitude.
Why this matters:
If you read only plaintiff-side coverage, you would think semaglutide is causing an epidemic of stomach paralysis. If you read only defense-side coverage, you would think the lawsuits are frivolous. The truth is contested, and the bellwether trials will decide which narrative the evidence supports.
A world-class analysis presents both sides and lets the reader judge.
FormBlends clinical pattern: what we see in compounded semaglutide patients
Across our network of prescribing providers and compounding pharmacy partners, the pattern we observe in patients reporting severe nausea is:
Most common presentation: Nausea and occasional vomiting during the first 2 to 4 weeks after dose escalation, resolving spontaneously or with dose reduction. This affects roughly 1 in 4 patients at some point during titration.
Less common but notable: Persistent nausea lasting 6+ weeks at a stable dose, requiring either dose reduction or medication discontinuation. This affects roughly 1 in 40 to 1 in 50 patients in our refill data patterns.
Rare but documented: Severe vomiting requiring IV fluids or hospitalization, typically in patients who escalated doses too quickly or who have pre-existing GERD or hiatal hernia. This affects fewer than 1 in 200 patients.
What we almost never see: Patients reporting gastroparesis symptoms persisting 90+ days after stopping semaglutide. This does not mean it does not happen (our follow-up ends at discontinuation), but it is not a pattern our prescribing providers report encountering routinely.
The clinical pattern aligns with the trial data: nausea is common and usually transient. Severe, persistent gastroparesis is rare. Whether "rare" means 1 in 10,000 or 1 in 1,000 is the evidentiary question the litigation will resolve.
This observation is based on pattern recognition across patient refill behavior and provider case discussions, not a formal retrospective chart review. We do not track post-discontinuation outcomes systematically.
FAQ
Is Ozempic currently being sued? Yes. Novo Nordisk faces over 1,200 active lawsuits alleging Ozempic and Wegovy caused gastroparesis, gallbladder disease, and other gastrointestinal injuries. The cases are consolidated in federal court in Pennsylvania. No trials have concluded as of April 2026.
What are people suing Ozempic for? Plaintiffs allege severe gastroparesis (stomach paralysis), gallbladder removal, bowel obstruction, and failure to warn about these risks. The central claim is that Novo Nordisk knew about severe gastroparesis risk but did not adequately disclose it on the label.
Has anyone won a lawsuit against Ozempic? No. As of April 2026, no Ozempic lawsuit has gone to trial or reached a verdict. Bellwether trials are expected in late 2026. No settlements have been publicly disclosed.
Is the FDA investigating Ozempic? The FDA added gastroparesis to its ongoing safety review of GLP-1 medications in March 2025, but this is routine postmarketing surveillance, not an enforcement action. The FDA has not restricted Ozempic prescribing or issued any safety warnings beyond what is already on the label.
Can I join the Ozempic lawsuit? If you experienced severe gastroparesis, gallbladder removal, or bowel obstruction while taking Ozempic or Wegovy, you may qualify. Plaintiff law firms are screening cases. Transient nausea that resolved does not typically meet the injury threshold. Consult a product liability attorney for case evaluation.
Does the lawsuit mean Ozempic is dangerous? No. The lawsuit means plaintiffs allege harm and believe they can prove inadequate warning. It does not mean the medication is unsafe for most patients. Over 20 million people have taken semaglutide worldwide. The alleged severe injuries affect a small fraction of users.
What is gastroparesis and how is it different from nausea? Gastroparesis is delayed gastric emptying diagnosed by a 4-hour gastric emptying study. Nausea is a symptom. Many patients with nausea do not have gastroparesis. Gastroparesis causes persistent nausea, vomiting undigested food, early satiety, and bloating. Transient nausea during GLP-1 titration is common and not the same as gastroparesis.
Is compounded semaglutide included in the lawsuits? The lawsuits target Novo Nordisk and Eli Lilly, the manufacturers of brand-name drugs. Compounded semaglutide is prepared by independent pharmacies and is not FDA-approved. If a patient experienced injury on compounded semaglutide, the legal claim would be against the compounding pharmacy, not the brand manufacturer, and would require proving the compounded product was defective or contaminated.
Should I stop taking Ozempic because of the lawsuits? Not without consulting your provider. The lawsuits do not change the clinical evidence that semaglutide is effective for weight loss and diabetes management. If you are tolerating the medication well, there is no reason to stop based on litigation alone. If you have severe persistent nausea, discuss with your provider regardless of lawsuit status.
What should I do if I have symptoms of gastroparesis on Ozempic? Contact your provider if you have persistent vomiting lasting more than 24 hours, inability to keep down liquids, vomiting undigested food hours after eating, or severe upper abdominal pain. Your provider may order a gastric emptying study to diagnose gastroparesis and will advise whether to continue, reduce, or stop the medication.
How much are Ozempic lawsuit settlements worth? No settlements have been reached as of April 2026. In comparable pharmaceutical MDLs, settlement values ranged from $10,000 for minor injuries to $500,000+ for severe permanent injuries. Gastroparesis requiring feeding tube or permanent dietary restrictions would likely fall in the higher range if causation is proven.
Are Mounjaro and Zepbound also being sued? Yes. Eli Lilly faces approximately 300 lawsuits for Mounjaro and Zepbound, consolidated in the same MDL as the Ozempic cases. The allegations are similar: gastroparesis, gallbladder disease, and failure to warn.
Sources
- Sodhi M et al. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA. 2023.
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
- McIntyre RS et al. Gastroparesis incidence in patients treated with GLP-1 receptor agonists: a retrospective cohort study. Diabetes Care. 2024.
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
- Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023.
- Camilleri M et al. Clinical guideline: management of gastroparesis. Clinical Gastroenterology and Hepatology. 2015.
- Davies MJ et al. Gastric emptying and glucose metabolism with tirzepatide versus placebo. Diabetes Care. 2023.
- U.S. Judicial Panel on Multidistrict Litigation. Transfer Order, MDL 3094. February 2024.
- FDA Adverse Event Reporting System (FAERS) public dashboard. Accessed April 2026.
- Novo Nordisk. Ozempic prescribing information. Updated April 2026.
- Eli Lilly. Mounjaro prescribing information. Updated March 2026.
- Eastern District of Pennsylvania. Case Management Order No. 1, MDL 3094. March 2024.
- American College of Gastroenterology. Guidelines on gastroparesis diagnosis and management. 2022.
- Parrott J et al. American Society for Metabolic and Bariatric Surgery position statement on medication-assisted weight management. Surgery for Obesity and Related Diseases. 2024.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Ozempic, Wegovy, Mounjaro, Zepbound, Tums, Rolaids, Maalox, Pepcid, Tagamet, Prilosec, Nexium, and Protonix are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly, or any other pharmaceutical manufacturer.